Cabaletta Bio Q3 EPS $(0.37) Beats $(0.40) Estimate; Cash, Cash Equivalents And Short-term Investments Of $164.4M Expected To Support Operations Into The Fourth Quarter Of 2025
Portfolio Pulse from Benzinga Newsdesk
Cabaletta Bio reported Q3 losses of $(0.37) per share, beating the analyst consensus estimate of $(0.40) by 7.5%. This is a 5.13% increase over losses from the same period last year. The company's cash, cash equivalents and short-term investments of $164.4M are expected to support operations into Q4 2025.
November 09, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cabaletta Bio's Q3 earnings beat estimates, and its cash position is expected to support operations until Q4 2025.
Cabaletta Bio reported better than expected Q3 earnings, which is generally a positive signal for the stock. Additionally, the company's strong cash position reduces financial risk and provides operational stability, which is also positive for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100